Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Strides Pharma Science Limited, commonly known as Strides Pharma Science or Strides, is a leading global pharmaceutical company with its headquarters in Bengaluru, India. Established in 1990, Strides has developed a significant international footprint, operating across key markets including the USA, Africa, Central and Eastern Europe (CEE), and other emerging regions.
As a prominent player in pharmaceutical preparation manufacturing, Strides Pharma Science specialises in developing and producing a diverse portfolio of high-quality finished dosages, complex generics, biopharmaceuticals, and specialty products. The company leverages robust R&D capabilities and a vertically integrated business model to ensure the delivery of affordable and essential medicines. Its commitment to manufacturing excellence underpins its strong position in the global pharmaceutical landscape.
-3 vs industry average
Strides Pharma Science’s score of 39 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Strides Pharma Science, an Indian pharmaceutical manufacturer, reported its total carbon emissions for 2025 as about 70.2 million kg CO2e. This includes approximately 5.38 million kg CO2e from Scope 1 emissions, 17.1 million kg CO2e from Scope 2 emissions, and about 47.8 million kg CO2e from Scope 3 emissions.
For 2024, the company's combined Scope 1 and Scope 2 emissions were approximately 25.2 million kg CO2e, with about 5.33 million kg CO2e from Scope 1 and 19.9 million kg CO2e from Scope 2. In 2023, the combined Scope 1 and Scope 2 emissions were around 24 million kg CO2e, comprising about 4.49 million kg CO2e from Scope 1 and 19.5 million kg CO2e from Scope 2. For 2022, combined Scope 1 and Scope 2 emissions were approximately 26.2 million kg CO2e, with roughly 6.21 million kg CO2e from Scope 1 and 19.96 million kg CO2e from Scope 2.
Strides Pharma Science is committed to a decarbonisation strategy. They aim to reduce absolute Scope 1 and Scope 2 emissions by 42% by FY2030, using FY2023 as the base year. The company is also formulating a long-term strategy and roadmap to contribute to the global Net Zero agenda for both Scope 1 and Scope 2 emissions, with a target year of 2050. Strides Pharma Science Limited is committed to Net Zero, as confirmed by the Science Based Targets initiative (SBTi).
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Strides Pharma Science’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more